A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of dementia.

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Novo Nordisk's (NVO) downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ability to maintain a market lead in the obesity drug space. The maker ...